Proceeding of International Conference on Precision Health in Industrial Revolution 4.0 (IC-PHIR), 26-27th August 2023 (pS1-S28)

Rare diseases present intricate diagnostic challenges, particularly within diverse populations like Malaysia.Malaysia's genetic diversity, stemming from its multicultural makeup, underscores the urgency of transforming rare disease diagnosis.Conventional diagnostic methods often fall short in uncovering the genetic variants responsible for these conditions, leading to misdiagnoses or diagnostic delays.Recognizing the potential of innovative approaches is crucial for addressing this gap.Transforming rare disease diagnosis necessitates the collaboration of multiple stakeholders.Collaborations between research institutions and private companies can drive innovation, making advanced diagnostics more accessible and affordable, while government entities provide policy frameworks and funding support.Policy initiatives can incentivize private sector involvement in rare disease research and diagnostics.Funding for research, infrastructure development, and training programs can facilitate the integration of genomic insights into clinical practice.Regulatory frameworks can ensure the ethical and responsible use of genetic information while protecting patient rights and privacy.On successful example of such endeavor is the 100,000 Genomes Project, a partnership between the government, National Health Service, and private companies, aimed to sequence 100,000 genomes from patients with rare diseases and cancers.This initiative had revolutionized diagnostics and personalized treatments.In 2023, a group of clinicians and researchers in Malaysia have come together in collaboration to set up the Consortium of Genomics for Rare and Neurological Diseases with a shared vision of improving patient outcomes and healthcare quality of patients with rare and neurological diseases.The main focus of the consortium is to use Next-generation sequencing (NGS) platform in the quest to identify elusive genetic variants responsible for rare diseases.The ability to uncover intricate genetic variations, especially within the context of a diverse population, holds immense promise for accurate diagnosis, novel therapeutic avenues, and enhanced patient care.We believed that by harnessing the collective strengths of all stakeholders, Malaysia can revolutionize diagnosis and management of rare and neurological disease, improving the lives of affected individuals and families.